Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda Van de Poël

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
ACS Medicinal Chemistry Letters|August 16, 2019
DPP1 Inhibitors: Exploring the Role of Water in the S2 Pocket of DPP1 with Substituted PyrrolidinesHelena Käck, Kevin Doyle, Samantha J Hughes, et al.
Journal of Medicinal Chemistry|October 4, 2016
Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986)Kevin Doyle, Hans Lönn, Helena Käck, et al.
Journal of Medicinal Chemistry|March 30, 2021
Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington's DiseaseAmanda Van de Poël, Leticia Toledo-Sherman, Perla Breccia, et al.
Journal of Medicinal Chemistry|March 7, 2019
Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease ModelsLeticia Toledo-Sherman, Perla Breccia, Roger Cachope, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
ACS Medicinal Chemistry Letters|August 16, 2019
DPP1 Inhibitors: Exploring the Role of Water in the S2 Pocket of DPP1 with Substituted PyrrolidinesHelena Käck, Kevin Doyle, Samantha J Hughes, et al.
Journal of Medicinal Chemistry|October 4, 2016
Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986)Kevin Doyle, Hans Lönn, Helena Käck, et al.
Journal of Medicinal Chemistry|March 30, 2021
Structure-Based Exploration of Selectivity for ATM Inhibitors in Huntington's DiseaseAmanda Van de Poël, Leticia Toledo-Sherman, Perla Breccia, et al.
Journal of Medicinal Chemistry|March 7, 2019
Optimization of Potent and Selective Ataxia Telangiectasia-Mutated Inhibitors Suitable for a Proof-of-Concept Study in Huntington's Disease ModelsLeticia Toledo-Sherman, Perla Breccia, Roger Cachope, et al.
Pageof 1